FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma - Oncology - Cancer

Source: FDA Center for Drug Evaluation and Research - What's New - July 27, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news